Symposium:
155. Big Beasts of Infectious Disease
Saturday, October 5, 2013: 8:30 AM-10:00 AM
Room: The Moscone Center: 120-125
Co-organized with the Center for Global Health Policy

Learning Objectives:

At the conclusion of this session, regarding each Beast, participants will be able to:

  • outline current trends in epidemiology of  the infection
  • discuss recent discoveries in the pathogenesis of the disease
  • review current literature on diagnosis
  • describe effectiveness of current approaches to treatment and prevention

Target Audience: public health practitioners, members-in-training, infectious diseases physicians, infectious diseases pediatricians, fellows, clinicians, academicians

Tracks: Pediatric ID, HIV-STD-TB, Global ID, Adult ID

Moderator:  Robert Read, MD, FIDSA, University of Southampton

Presentations:

8:30 AM
Tuberculosis
Timothy Sterling, MD

9:00 AM
Norovirus
Robert Atmar, MD, FSHEA, FIDSA

9:30 AM
Staphylococcal Disease
Henry Chambers, MD, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-090-L01-P

Disclosures:

R. Read, Novartis vaccines and diagnostics: Scientific Advisor, Consulting fee

H. Chambers, Astra Zeneca: Scientific Advisor, Consulting fee
Pfizer: Scientific Advisor, Consulting fee
Trius: Grant Investigator, Scientific Advisor and Stock Options, Consulting fee, Grant recipient and Stock Options
Theravance: Scientific Advisor, Consulting fee

T. Sterling, sanofi aventis: Consultant, Consulting fee and One day of consultation provided in 2012.
Otsuka: Data safety monitoring board member for a clinical trial, Consulting fee
Pfizer: Grant Investigator, Research grant and Research grant to Vanderbilt. HIV observational cohort studies
Bristol Myers Squibb: Grant Investigator, Research grant and Research grant to Vanderbilt. HIV observational cohort studies
Virco: Grant Investigator, Research grant and Research grant to Vanderbilt. HIV observational cohort studies

R. Atmar, Takeda Pharmaceuticals/LigoCyte: Research Contractor and Scientific Advisor, Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.